Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of live attenuated yellow fever vaccine (vYF) in adults
jRCT2031250418Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SP0218 in yellow fever, sponsored by Sanofi. Primary endpoint: Seroconversion rate to yellow fever virus in yellow fever-naive participants. Started Oct 2025; status: completed.
02
Drugs
SP0218
03
Conditions
yellow fever
Beyond the preview
Go deeper on jRCT2031250418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250418.